Lipid Panel

LDL-cholesterol measures total cholesterol content within LDL particles — but a small number of large, buoyant LDL particles carries more cholesterol than a large number of small, dense particles. ApoB counts the particles directly — one ApoB protein per atherogenic lipoprotein particle — making it a direct measure of cardiovascular risk regardless of the size or cholesterol content of those particles. In insulin-resistant patients — including many perimenopausal women — LDL-C can appear acceptable while ApoB is elevated, because insulin resistance specifically promotes small, dense LDL production that keeps total cholesterol relatively stable while dramatically increasing particle count and risk. The lipid panel tells you the cholesterol story; ApoB tells you the particle story.

Fasting triglycerides above 150 mg/dL are a sensitive indicator of insulin resistance and metabolic dysfunction. Elevated triglycerides reflect the liver overproducing VLDL particles in response to excess insulin and carbohydrate load. They also directly elevate cardiovascular risk. Very high triglycerides (above 500 mg/dL) can cause acute pancreatitis. For patients with elevated triglycerides, metabolic intervention — not just statin therapy — is typically the most appropriate first-line strategy.

Lipoprotein(a) — Lp(a) — is a genetically determined lipoprotein that carries additional atherogenic and thrombotic properties beyond standard LDL. Elevated Lp(a) is an independent cardiovascular risk factor not reducible by standard lipid-lowering therapy (statins do not lower Lp(a)). It is estimated to affect 20% of the population and is particularly relevant for assessing risk in individuals with family history of early heart disease. SPOKEmed includes Lp(a) testing when indicated based on personal and family history.